ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS
Clinical trials for ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS explained in plain language.
Never miss a new study
Get alerted when new ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS trials appear
Sign up with your email to follow new studies for ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Recruiting nowThis study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participan…
Matched conditions: ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo aims to ease myasthenia gravis symptoms
Disease control Recruiting nowThis study is testing two drugs, efgartigimod and empasiprubart, given by IV, to see if they are safe and work well for people with myasthenia gravis (MG). The goal is to reduce side effects and improve quality of life. About 70 adults with MG are being recruited.
Matched conditions: ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo aims to ease muscle weakness in myasthenia gravis
Disease control Recruiting nowThis study tests whether adding empasiprubart to the existing drug efgartigimod can improve symptoms and daily function in people with generalized myasthenia gravis who still have symptoms on efgartigimod alone. About 70 participants will receive both drugs intravenously. The mai…
Matched conditions: ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC